(Q44211870)

30 November 2017

Histopathologic characteristics predicting HER-2/neu amplification in breast cancer (English)

1 reference

30 November 2017

Raquel Prati

1

1 reference

30 November 2017

Sophia K Apple

2

1 reference

30 November 2017

Jianbo He

3

1 reference

30 November 2017

Jeffrey A Gornbein

4

1 reference

30 November 2017

Helena R Chang

5

1 reference

30 November 2017

1 November 2005

1 reference

30 November 2017

1 reference

30 November 2017

11

1 reference

30 November 2017

6

1 reference

30 November 2017

433-439

1 reference

Targeted therapy in breast cancer: the HER-2/neu gene and protein

30 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Moving forward: Herceptin in the adjuvant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Her-2/neu and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Evaluating HER2 amplification and overexpression in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Clinical Experience with Trastuzumab (Herceptin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Emerging technologies for HER2 testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

HER-2/neu as a predictive marker of response to breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

HER-2 testing in breast cancer using parallel tissue-based methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Current status of HER2 testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Assessment of HER‐2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Do we need HER-2/neu testing for all patients with primary breast carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1075-122X.2005.00125.X

10.1111/J.1075-122X.2005.00125.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference